KR20100122376A - Composition for anti-inflammation - Google Patents

Abstract

PURPOSE: A composition containing kiwi leaf extract for anti-inflammation is provided to apply to atopic dermatitis. CONSTITUTION: A composition for anti-inflammation contains kiwi leaf extract as an active ingredient. The extract is obtained using water, distilled water, ethanol or mixture solvent thereof. The composition is a pharmaceutical composition. The composition is also a cosmetic composition for relieving atopic dermatitis. A composition for relieving atopic dermatitis contains kiwi pulp extract as an active ingredient.

Description

Anti-inflammatory composition {Composition for Anti-inflammation}

The present invention relates to an anti-inflammatory composition, and more particularly, to an anti-inflammatory composition comprising a sesame leaf extract as an active ingredient.

Inflammation is the body's defense against external infections such as physical and chemical stimuli, bacteria, fungi, viruses, and allergens.

Inflammatory responses are part of the innate immune response, and as in other animals, the innate immune response in humans begins by recognizing and attacking non-self through patterns of cell surfaces where macrophages are specifically present in pathogens. During the inflammatory reaction, plasma accumulates at the site of inflammation, diluting the toxicity secreted by bacteria, increasing blood flow, and accompanied by symptoms such as erythema, pain, edema, and fever.

These inflammatory responses involve a variety of biochemical phenomena, especially cyclooxygenase (COX), which is associated with the biosynthesis of nitric oxide synthase (NOS) and various prostaglandins. It is known as a medium.

There are three isomers of NOS, which are endotoxins of bacteria such as calcium- or capmodin-dependent eNOS (endothelial NOS), nNOS (neurotrophic NOS), and LPS (lipopolysaccharide) or IL-1β, TNF-α, IL There are iNOS (inducible NOS) induced by several inflammatory cytokines such as -6, IL-8 and IL-12, which produce nitric oxide (NO) from L-arginine.

NO produced by eNOS or nNOS plays an important role in maintaining homeostasis by performing various physiological reactions related to blood pressure control, neurotransmitter, learning, memory, etc. It is known to be involved in various inflammatory diseases such as transplant rejection, autoimmune diseases and neuronal death (Moncade S. et al, Pharmacol. Rev., 1991, 43, 109; Nature Medicine, 2001, 7, 1138; Mu , MM, J. Endotoxic Res. 7, p341, 2001).

The COX enzyme has hydroperoxidase (HOX) activity with COX function and synthesizes PGG ₂ and PGH ₂ intermediates from arachidonic acid, and these compounds include PGE ₂ , PGF ₂ , PGD ₂ , and prostacyclin. And thromboxin A ₂ (thromboxane A2, TxA2). Among the functions of COX, the function of PGH synthase is involved in pain and inflammatory responses through the synthesis of PGE ₂ .

There are two subtypes of COX and COX-1 is always expressed in most tissues, whereas COX-2 is rapidly induced by inflammatory cytokines and plays an important role in the inflammatory response.

Thus, iNOX inhibitors and COX-2 inhibitors can be used as therapeutic agents for inflammatory diseases.

The present invention provides an anti-inflammatory composition using a sesame seed extract having inflammatory cytokine production inhibitory activity, iNOS production inhibitory activity, COX-2 production inhibitory activity and the like.

Other objects, specific embodiments, and the like of the present invention will be presented below.

The present inventors made 16 kinds of extracts using Halla gold, Jessie gold, Jessie sweet, and North China 94 leaves, fruit whole, pulp, and rind, and 80% ethanol as the extraction solvent. , NO (Nitric Oxide) production inhibitory activity, iNOS (inducible NOS) production inhibitory activity, COX-2 production inhibitory activity and prostagladin E ₂ (PGE ₂ ) production inhibitory activity was examined. Regardless of the variety used, it was confirmed that it had high anti-inflammatory activity overall.

The present invention provides anti-inflammatory compositions based on these experimental results.

Therefore, the anti-inflammatory composition of the present invention is characterized in that the active ingredient contains sesame leaf extract as an active ingredient.

As used herein, the term "perilla" refers to a deciduous vine plant ( Acinidia chinensis ) of the dicotyledonous plantary membrane pericarpaceae. Preferably the Halla gold (new varieties developed in 2007 by the Nanji Agricultural Research Institute in Jeju, Jeju) used in the embodiment of the present invention, Jessie Gold (new varieties developed by the Nanji Agricultural Research Institute in Rural Development Administration, Jeju, [Nanji Agricultural Test Research Project] Annual Report, 2006 / National Agricultural Research Institute, Rural Development Administration), Jessie Suite (New varieties developed by the Nanji Agricultural Research Institute, Rural Development Administration, Jeju), Journal of Nanji Agricultural Research, Vol. 1, No. 5 (2004. Spring). 35-37) or North China 94 (the first species of fruit that was first discovered in 1994 at the Jeju Agricultural Experiment Station and named North Korea 94 in 1998).

In addition, in the present specification, "anti-inflammatory" is meant to include amelioration, treatment of inflammatory diseases and inhibition / delay of onset of such diseases as defined below.

In addition, in this specification, an "extract" means what was obtained using a sesame leaf as an extraction object, and using water, distilled water, ethanol, or a mixed solvent thereof as an extraction solvent. When the extract is obtained using an extraction solvent, any method such as hot water, warming, cooling, ultrasonic spinning, stirring, or a method of mixing them may be used. The present inventors have not been disclosed in the following Examples and Experimental Examples, but when using any of the extraction method using the extracting solvent, although there is a difference in activity, it was confirmed that all have anti-inflammatory activity.

In the present specification, the "inflammatory disease" may be defined as any condition specified by a local or systemic biological defense response against external physical and chemical stimuli or infection of an external infectious agent such as bacteria, fungi, viruses, and various allergens. . This response activates various inflammatory mediators and enzymes associated with immune cells (eg iNOS, COX-2, etc.), secretion of inflammatory mediators (eg NO, TNF-α, IL-6, IL-1β, PGE ₂₎ . ), Accompanied by a series of complex physiological reactions such as fluid infiltration, cell migration, tissue destruction, etc., and are manifested externally by symptoms such as erythema, pain, edema, fever, deterioration or loss of certain functions of the body. The inflammatory disease may be acute, chronic, ulcerative, allergic or necrotic, so as long as any disease is included in the definition of an inflammatory disease as above, whether it is acute, chronic, ulcerative, allergic or Irrespective of necrosis Specifically, the inflammatory diseases include asthma, allergic and non-allergic rhinitis, chronic and acute rhinitis, chronic and acute gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, pulmonary fibrosis Irritable bowel syndrome, inflammatory pain, migraines, headache, back pain, fibromyalgia, fascia disease, viral infections (eg, type C infections), bacterial infections, fungal infections, burns, surgical or dental wounds, Prostaglandin E excess syndrome, atherosclerosis, gout, arthritis, rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, irisitis, scleritis, uveitis, dermatitis (including atopic dermatitis), eczema, multiple sclerosis Will be included.

However, preferably, the inflammatory disease means atopic dermatitis. The following Examples and Experimental Examples of the present invention is the thymus and activation-regulation chemokine (TARC) and macrophage of chemokines associated with atopic dermatitis in HaCaT cells, which are human dermal keratinocyte lines stimulated with interferon-γ -derived chemokine) has been shown to inhibit the production. TARC and MDC specifically bind to CC chemokine receptor-4 (CCR4) when atopic dermatitis occurs, of which TARC selectively regulates the migration of Th2 cells, and MDC is a monocyte, monocyte-derived dendritic cell, or natural killer It is known to regulate migration of cells and the like. In vitro experiments suggest that stimulation of HaCaT cells, a human keratinocyte cell line with interferon gamma and tumor necrosis factors, results in a large amount of MDC and TARC expression and can be used as a therapeutic agent for atopic dermatitis. (Horikawa et. Al., Int. Immunol., 14 (7) 767-773, 2002).

Referring to the Examples and Experimental Examples below, it can be seen that even the extract of sesame bark extract is excellent in the MDC and TARC production inhibitory activity. In particular, the treatment of Jessie sweet rind extract of Jessie sweet rind inhibited MDC production by 50% or more. In addition, the inhibition of TARC production could be confirmed by inhibiting 50% or more of North China 94 rind, Halla gold rind, and Jessie sweet rind extract.

Therefore, when the inflammatory composition of the present invention is identified as the composition for improving atopic dermatitis, the active ingredient should be understood to include sesame rind extract in addition to sesame leaf extract.

As used herein, the term "active ingredient" alone refers to a component that can exhibit the desired activity or exhibit itself with a carrier which is inactive.

In another aspect, the present invention relates to an iNOS inhibitor composition comprising the extract as described above as an active ingredient.

As mentioned above, inhibition of iNOS can inhibit the production of NO leading to improvement of inflammatory disease.

The following experimental example of the present invention shows that the extract of the sangha tang of the present invention inhibits the production of NO and inhibits the expression of iNOS at the gene and protein levels, and inhibits the production of cytokines known to induce the expression of iNOS. Is showing.

As used herein, "iNOS inhibition" is meant to include inhibition of expression of iNOS gene and inhibition of iNOS production, and meaning including inhibition and / or reduction of NO production whatever the intermediate mechanism.

In another aspect, the present invention relates to a COX-2 inhibitor composition comprising the extract as described above as an active ingredient.

As mentioned above, inhibition of COX may inhibit the production of PGE ₂ resulting in improvement of inflammatory disease.

The following examples of the present invention show that the sesame leaf extract of the present invention inhibits the production of PGE ₂ and inhibits the expression of COX-2 at the gene and protein levels, and is known to induce the expression of COX-2. It has been shown to inhibit the production of cain.

As used herein, the term "COX-2 inhibition" is meant to include inhibition of expression of COX-2 gene and inhibition of COX-2 production, and meaning including inhibition and / or reduction of the production of PGE ₂ whatever the intermediate mechanism. to be.

Meanwhile, the composition of the present invention (ie, inflammatory disease improving agent composition, iNOS inhibitor composition, and COX-2 inhibitor composition; referred to below) is intended to treat the sesame leaf extract as defined in the active ingredient according to the use, formulation, purpose of formulation, and the like. It may be included in any amount (effective amount) as long as it can exhibit an improving activity of an inflammatory disease, a conventional effective amount will be determined within the range of 0.001% to 15% by weight based on the total weight of the composition. The term "effective amount" as used herein refers to the amount of an effective ingredient capable of inducing the improvement, treatment, or suppression / delay of the development of such pathological symptoms in a mammal, preferably a human, to which it is applied. Such effective amounts can be determined experimentally within the range of ordinary skill in the art.

Subjects to which the compositions of the invention can be applied (prescribed) are mammals and humans, in particular humans.

The composition of the present invention can be used as a pharmaceutical composition in a specific embodiment.

The pharmaceutical composition of the present invention includes oral formulations (tablets, suspensions, granules, emulsions, capsules, syrups, etc.), parenteral formulations including pharmaceutically acceptable carriers, excipients, etc. Sterile injectable aqueous or oily suspensions), topical formulations (solutions, creams, ointments, gels, lotions, patches) and the like.

As used herein, "pharmaceutically acceptable" means that the subject of application (prescription) does not have more toxicity (adequately low toxicity) to which the subject of application (prescription) is adaptable without inhibiting the activity of the active ingredient.

Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (such as corn starch, potato starch, etc.), cellulose, derivatives thereof (such as sodium carboxymethyl cellulose, ethylcellulose, etc.) malt, gelatin, talc, solids Lubricants (e.g. stearic acid, magnesium stearate, etc.), calcium sulfate, vegetable oils (e.g. peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (e.g. propylene glycol, glycerin, etc.), alginic acid, emulsifiers (e.g. TWEENS), wetting agents (e.g. Sodium lauryl sulfate), colorants, flavoring agents, tableting agents, stabilizers, antioxidants, preservatives, water, saline, phosphate buffer solutions and the like. The carrier may be selected from one or more of suitable pharmaceutical formulations according to the formulation of the pharmaceutical composition of the present invention.

Excipients may be selected and used according to the formulation of the pharmaceutical composition of the present invention, for example, when the pharmaceutical composition of the present invention is prepared with an aqueous suspending agent, suitable excipients are sodium carboxymethyl cellulose, methyl cellulose, hydropropylmethylcellulose And suspending agents and dispersing agents such as sodium alginate and polyvinylpyrrolidone. Suitable excipients when prepared from injection solutions include Ringer's solution, isotonic sodium chloride, and the like.

The pharmaceutical compositions of the present invention may be administered orally or parenterally, and may optionally be administered topically, as in the case of atopic dermatitis compositions.

The daily dose of the pharmaceutical composition of the present invention is usually 0.001 to 150 mg / kg body weight, and may be administered once or several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as the route of administration, the age, sex, weight of the patient, the severity of the patient and the like, the dosage may limit the scope of the present invention in any aspect. It should not be understood as.

The composition of the present invention, in particular, the atopic dermatitis improving agent composition of the present invention may be regarded as a cosmetic composition in a specific embodiment.

When the composition for skin whitening of the present invention is understood as a cosmetic composition, the cosmetic composition can be prepared in various forms, for example, emulsion, lotion, cream (oil-in-water type, water-in-oil type, multiphase), solution, suspension (Anhydrous and aqueous), anhydrous products (oil and glycols), gels, masks, packs or powders and the like.

The cosmetic composition for skin whitening of the present invention may include an acceptable carrier in cosmetic preparations in addition to the extracts of Thyme biloba / Peel.

Herein, "acceptable carriers in cosmetic preparations" are compounds or compositions already known and used that may be included in cosmetic preparations, or compounds or compositions which will be developed in the future, which have no toxicity, instability or irritation more than the body can adapt to in contact with the skin. Say that.

The carrier may be included in the cosmetic composition for skin whitening of the present invention at about 1% by weight to about 99.99% by weight, preferably about 50% to about 99% by weight of the composition.

However, since the ratio depends on the form of the above-described preparation of the cosmetic of the present invention and its specific application site (face or hand) or its preferred application amount, the ratio is in any aspect the scope of the present invention. It should not be understood as limiting.

Meanwhile, examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosity modifiers, emulsions, stabilizers, sunscreen agents, colorants, fragrances, and the like.

Alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, humectants, viscosity modifiers, emulsions, stabilizers, sunscreens, colorants, compounds / compositions that can be used as fragrances, etc., which can be used as the carrier are already known in the art. As a result, those skilled in the art can select and use appropriate materials / compositions.

As described above, the present invention can provide an anti-inflammatory composition. The anti-inflammatory composition of the present invention can be usefully applied to atopic dermatitis.

Hereinafter, the present invention will be described with reference to Examples. However, the scope of the present invention is not limited to these examples.

Example 1 Preparation of Sesame Seed Extract

The cultivars used for the extraction were A. chinensis (Golden Yellow) × A. deliciosa (Songongu), A. chinensis (Golden Yellow) × A. chinensis (Songongu), and Jesse Sweet [ A. chinensis (apple) × A. deliciosa (Tomuri)].

The extracts were leached with 80% ethanol (EtOH) and leached with 80% ethanol (EtOH), and then Whatman No. 2 (Whatman No. 2) The filtrate was concentrated under reduced pressure, concentrated and powdered to prepare a total of 16 extracts. Each powder sample was stored at -20 ° C until testing.

Example 2 Evaluation of Anti-inflammatory Activity of Sesame Seed Extract

Example 2-1 Cell Culture

RAW 264.7 cells, a macrophage cell line, were obtained from Korean Cell Line Bank (KCLB) at 37 ° C using DMEM medium containing 100 units / mL of penicillin-streptomycin and 10% fetal bovine serum (FBS). , 5% CO2 incubator and subculture every 3 days.

Example 2-2 Evaluation of NO Production Inhibitory Activity

RAW264.7 cells were adjusted to 1.5 × 10 ⁵ cells / mL using DMEM medium with 10% FBS, inoculated into 48 well plates, and treated with extract samples and LPS (1 μg / mL) simultaneously for 24 hours. Incubated. The amount of NO produced was measured in the form of NO ₂ − present in the cell culture solution using Griess reagent. Mix 100 μL of cell culture supernatant with 100 μL of Griess reagent [1% (w / v) sulfanilamide, 0.1% (w / v) naphylethylenediamine in 2.5% (v / v) phosphoric acid] for 10 minutes on 96 well plates. After absorbance was measured at 530 nm. The amount of NO produced was compared with sodium nitrite (NaNO ₂ ) as standard.

The results are shown in Table 1 below.

The experimental results showed that the concentration of the leaf extract of all the varieties of lyra used in the high NO inhibitory activity.

Example 2-3 Evaluation of iNOS and COX Expression Inhibition Activity

After culturing, the cells were collected and washed 2-3 times with PBS (Phosphate Buffered Saline), followed by lysis for 30 minutes with the addition of 1 mL of lysis buffer, followed by centrifugation at 12,000 rpm for 20 minutes to remove cell membrane components. Protein concentration was quantified using the Bio-Rad Protein Assay Kit by standardizing BSA (Bovine serum albumin). 30-50 μg of lysate was denatured by 8-12% mini gel SDS-PAGE (Poly Acrylamide Gel Electrophoresis), and transferred to PVDF membrane (BIO-RAD) at 200 mA for 2 hours. Membrane blocking was performed for 2 hours at room temperature in TTBS (TBS + 0.1% Tween 20) solution containing 5% skim milk. Anti-mouse iNOS (1: 1000) (Cell Signaling) was used as an antibody to examine the expression level of iNOS. Anti-mouse COX-2 (1: 1000) Cell Signaling) was diluted in TTBS solution, reacted at room temperature for 2 hours, and washed three times with TTBS. As a secondary antibody, anti-mouse IgG (Amersham Co.) conjugated with HRP (Horse Radish Peroxidase) was diluted 1: 5000, reacted at room temperature for 30 minutes, washed three times with TTBS, and then washed with ECL substrate (Amersham Cooxid). ), And then reacted for 1 to 3 minutes to the X-ray film.

The results are shown in FIGS. 1 and 2. It is a result showing the expression level of iNOS of Figure 1, Figure 2 is a result showing the expression level of COX-2.

In this case, the leaf extract showed a strong inhibitory effect of iNOS and COX-2 production, regardless of the cultivars similar to the NO production inhibitory effect.

In addition, the extracts of Hallagold pulp, Hubei 94 and Hallagold peels showed higher inhibitory effects on iNOS production than other fruit areas. It has been shown to work.

Example 2-4 Evaluation of Prostaglandin E ₂ (PGE ₂ ) Formation Inhibition Activity

RAW 264.7 cells, a Murine macrophage cell line, were adjusted to 1.5 × 10 ⁵ cells / mL using DMEM medium, inoculated in 24 well plates, and pre-incubated for 18 hours in a 5% CO2 incubator. The medium was then removed and cultured under the same conditions as the preculture by simultaneously treating 25 μL of the test substance prepared at 10-fold concentration (1 mg / mL) and fresh medium containing the final concentration of LPS of 450 μL (1 μg / mL). It was. After 24 hours, the supernatant was obtained by centrifugation (12,000 rpm, 3 min) of the culture medium to measure Prostaglandin E ₂ (PGE ₂ ). PGE ₂ was quantified using the PGE ₂ ELISA kit (R & D Systemes, Inc, USA).

The results are shown in Figure 3, showing a similar tendency to the inhibitory effect of the production of COX-2, especially in the leaf extract Jessegold varieties, fruit extracts, Halla gold varieties have a higher inhibitory effect than the other extracts Indicated

Example 2-5 Skin Cell Immune Test

Cells and Reagents

HaCaT cells, a modified keratinocyte cell line from Cheju National University, Korea, were distributed and treated in DMEM medium containing 100 units / ml penicillin-streptomycin and 10% fetal bovine serum (FBS) at 37 ° C and 5% CO ₂ incubator. Cultures were carried out and passaged once every 3 to 4 days. Human interferon-γ (hIFN-γ, recombinant E. coli) was obtained from Roche. The human MDC & TARC ELISA kit was purchased for R & D (Germany) and used in the experiment.

Skin Cell Culture and Cytotoxicity Assessment

HaCaT cells (3.0 × 10 ⁵ cells / ml) were incubated for 24 hours by co-treatment with test drug and IFN-γ (10 ng / ml) in DMEM medium without FBS, and then obtained culture medium for 5 minutes at 3,000 rpm. Centrifugation was performed. LDH activity was measured using a Non-Radioactive Cytotoxicity Assay kit (promega, USA). 50 μl of culture medium and 50 μl of reconstituted substrate mix obtained by centrifugation were put into a 96 well plate, and then reacted for 30 minutes at room temperature. Put the stop solution of ㎕ measured the absorbance at 490 nm. Average absorbance values were obtained for each sample group, and cytotoxicity was evaluated by comparing with the absorbance values of the control group (LDH control, 1: 5000).

MDC and TARC Generation and Quantification

HaCaT cells, a human keratinocyte cell line, were adjusted to 3 × 10 ⁵ cells / ml using DMEM medium, inoculated into 24 well plates, and pre-incubated for 18 hours in a 5% CO ₂ incubator. Thereafter, the medium was removed, and 50 μl of the test substance prepared at 10-fold concentration was added to 450 μl of a fresh medium (FBS (−)) containing hIFN-γ (final concentration of 10 ng / ml) and cultured under the same conditions as the previous culture. . After 24 hours, the MDC and TARC contents of the supernatant obtained by centrifugation (12,000 rpm, 3 min) in the culture medium were quantified using human MDC immunoassay and human TARC immunoassay kit (R & D, Germany), respectively. The r2 value of was 0.99 or more.

The results are shown with the cytotoxic effect in FIG. 4.

Induction of chemokines with IFN-γ (10 ng / mL) in HaCaT cells, which are modified keratinocytes, and treatment of natural extracts of the wild tuna, resulted in North Korean 94 in leaf extracts and North Korean 94 in Jessie sweet varieties. MDC production was inhibited by more than 50% when Jessie sweet skin extract was treated, and TARC production inhibition was also inhibited by 50% or more when treated with North North 94 leaf, North North 94 skin, Halla gold skin, and Jessie sweet skin extract.

1 is a result showing the effect of the extract of each part of the sesame seeds on iNOS, Figure 2 is a result showing the effect of the extract of each part of the sesame seeds on COX-2 expression.

Figure 3 is a result of the effect of the extract of each part of the sesame seeds on the inhibition of the production of PGE ₂ .

Figure 4 is a result of the effect of the extract of each part of the sesame seeds on the production inhibition of chemokine MDC and TARC. In Figure 4 1 to 4 is the North North 94 leaf extract, Halla gold leaf extract, Jessie sweet leaf extract and Jesse Gold leaf extract, 5 to 7 is the fruit, flesh and rind extract of North China 94, 8 to 10 of Halla Gold Fruit, pulp and rind extract, 11-13 are fruit, pulp and rind extracts of Jessie Sweet, and 14-16 are fruit, rind and rind extract of Jessie Gold.

Claims (10)

An anti-inflammatory composition comprising sesame leaf extract as an active ingredient. The method of claim 1, The extract is an anti-inflammatory composition, characterized in that obtained using water, distilled water, ethanol or a mixed solvent thereof. The method of claim 1, The anti-inflammatory properties include asthma, allergic and non-allergic rhinitis, chronic and acute rhinitis, chronic and acute gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, pulmonary fibrosis, irritability Bowel Syndrome, Inflammatory Pain, Migraine, Headache, Back Pain, Fibromyalgia, Fascia Disease, Viral Infection (eg, Type C Infection), Bacterial Infection, Fungal Infection, Burn, Surgical or Dental Surgery, Prostar Inflammatory disease selected from the group consisting of Gladin E hyperplasia, atherosclerosis, gout, arthritis, rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, irisitis, scleritis, uveitis, dermatitis, atopic dermatitis eczema and multiple sclerosis An anti-inflammatory composition, characterized in that it is used for the improvement of the disease. The method of claim 1, The sesame is anti-inflammatory composition, characterized in that selected from the group consisting of Halla gold, Jessie gold, Jesse twist and North Korea 94. The method according to any one of claims 1 to 4, The composition is an anti-inflammatory composition, characterized in that the pharmaceutical composition. The method according to any one of claims 1 to 4, The anti-inflammatory composition is an anti-inflammatory composition, characterized in that the atopic dermatitis improver cosmetic composition. An atopic dermatitis improving composition comprising a sesame rind extract as an active ingredient. The method of claim 7, wherein The sesame is atopic dermatitis improving composition, characterized in that one of North China 94, Halla gold and Jessie Suite. The method of claim 7, wherein The extract is atopic dermatitis improving composition, characterized in that obtained by using water, distilled water, ethanol or a mixed solvent thereof. The method according to any one of claims 7 to 9, The composition is an atopic dermatitis improving composition, characterized in that the cosmetic composition.

Images